Market Overview - The Global Refurbished Medical Imaging Equipment Market is projected to grow at a CAGR of 15.07% from 2026 to 2032, with a market value of USD 12,990.44 Million in 2024, expected to reach USD 40,056.03 Million by the end of the forecast period [1] Key Drivers - Cost-effectiveness and affordability are significant factors driving the market, as healthcare facilities, especially in developing countries, opt for refurbished equipment to maintain high-quality diagnostic capabilities within budget constraints [3] - The growing healthcare infrastructure in emerging markets is increasing the demand for cost-effective imaging solutions, making refurbished equipment a practical option for healthcare providers [4] - Sustainability and environmental concerns are positively impacting the market, as refurbishing medical imaging equipment helps reduce electronic waste and carbon footprint, aligning with global sustainability goals [5] Challenges - Concerns over quality and performance remain a challenge, as some medical professionals doubt the reliability of refurbished equipment, which may hinder market acceptance [7] - Stringent regulatory requirements pose obstacles, as meeting international standards can be challenging and costly, potentially discouraging smaller companies from entering the market [8] - Competition from new technologies in medical imaging may reduce the market share of refurbished equipment, particularly in developed regions where budget constraints are less significant [9] Geographical Insights - North America leads the market due to its strong healthcare infrastructure and favorable reimbursement policies, with hospitals increasingly seeking affordable solutions [10] - Europe follows closely, with rising demand in countries like Germany and the UK, while emerging markets in Asia-Pacific are rapidly gaining ground, presenting promising growth prospects [10] Market Segmentation - The market is segmented by product type, including X-ray devices, ultrasound systems, CT scanners, and MRI equipment [12] - Applications include oncology, cardiovascular, gynecology, and orthopedic [12] - End-users consist of hospitals, diagnostic centers, and ambulatory surgical centers [12] Key Players - Major players in the Global Refurbished Medical Imaging Equipment Market include Siemens Healthineers AG, Canon Medical Systems Corporation, Philips Healthcare, GE Healthcare, DRE Medical, and Atlantis Worldwide [11]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Aclarion, Inc. (ACON) is up 38% at $7.94 [3] - A SPAC III Acquisition Corp. (ASPC) is up 31% at $21.41 [3] - Nuvve Holding Corp. (NVVE) is up 23% at $4.32 [3] - Acrivon Therapeutics, Inc. (ACRV) is up 20% at $3.55 [3] - PMGC Holdings Inc. (ELAB) is up 16% at $6.76 [3] - Serina Therapeutics, Inc. (SER) is up 14% at $2.73 [3] - Regencell Bioscience Holdings Limited (RGC) is up 13% at $60.00 [3] - One Stop Systems, Inc. (OSS) is up 11% at $8.75 [3] - Anixa Biosciences, Inc. (ANIX) is up 9% at $3.60 [3] - Globus Medical, Inc. (GMED) is up 7% at $96.99 [3] Premarket Losers - Immuneering Corporation (IMRX) is down 23% at $6.34 [4] - Genelux Corporation (GNLX) is down 12% at $2.95 [4] - Erasca, Inc. (ERAS) is down 11% at $4.55 [4] - Phathom Pharmaceuticals, Inc. (PHAT) is down 10% at $16.10 [4] - Acurx Pharmaceuticals, Inc. (ACXP) is down 9% at $2.62 [4] - Evolution Metals & Technologies Corp. (EMAT) is down 8% at $17.34 [4] - Revolution Medicines, Inc. (RVMD) is down 7% at $95.14 [4] - Cardio Diagnostics Holdings, Inc. (CDIO) is down 7% at $2.59 [4] - Vestis Corporation (VSTS) is down 6% at $6.42 [4] - WORK Medical Technology Group LTD (WOK) is down 6% at $2.75 [4]

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except fixed income outside the U.S. posted positive returns. In addition, please check the fund’s top five holdings to know its best picks in 202 ...

Mineral Resources Ltd (Resmed CDI (MIN share price in focusThe ASX:MIN ) share price has risen 59.2% since the start of 2025. Meanwhile, the ASX:RMD ) share price is 19.6% away from its 52-week high. This article explains why it could be worth popping MIN and RMD shares on your watchlist.Mineral Resources Limited (MIN) is a diversified Australian mining company primarily focused on the extraction of lithium and iron ore in Western Australia.In addition to its mining operations, MIN offers mining and enginee ...

Group 1: Corporate Actions - Devyani International's board has approved a Scheme of Arrangement for the amalgamation with Sapphire Foods India Ltd, effective from April 1, 2026, with a share exchange ratio of 177 shares of Devyani for every 100 shares of Sapphire [1] - NLC India has transferred seven Renewable Energy Assets to its wholly owned subsidiary, NLC India Renewables Ltd, effective January 1, as per a Business Transfer Agreement [2] - Indegene's step down subsidiaries, Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc., have amalgamated to form Indegene Healthcare Canada Inc., effective January 1, 2026 [5] - Achyut Healthcare has received approval from BSE Limited to migrate its equity shares from the BSE SME platform to the BSE Main Board Platform, enhancing market access for investors [6] Group 2: Financial Developments - Vodafone Idea has received a GST penalty order of approximately ₹638 crore and plans to take legal action against it, following a recent relief on its Adjusted Gross Revenue dues [2] - Bharat Electronics Limited has secured additional orders worth ₹569 crore, including communication equipment and medical electronics [4] - Trident Lifeline has acquired an additional 9.04% stake in Trident Mediquip for approximately ₹4.42 crore [7] - Railtel Corporation has received a Letter of Acceptance for an order estimated at ₹56.71 crore from Assam Health Infrastructure Development & Management Society [9] Group 3: Project Announcements - K2 Infragen Ltd has announced receipt of a Letter of Acceptance for a ₹262 crore project from Indian Railways, focusing on traction substations and related infrastructure [8] - Olectra Greentech has commenced commercial operations for its Greenfield Electric Vehicle manufacturing facility in Hyderabad, with an annual production capacity of 2,500 buses [10] - Modis Navnirman Ltd has been appointed as the developer for the redevelopment of BOI Staff Sheetal Co-operative Housing Society in Mumbai, with an estimated Gross Development Value of ₹250 crore [11] Group 4: Regulatory Issues - Britannia Industries has received a tax demand order amounting to ₹108.50 crore for incorrect availment of input tax credit over six financial years [12]

U.S. stock futures swung between gains and losses on Tuesday after Monday’s declines. Futures of major benchmark indices were mixed.The Santa Claus rally, which began on Dec. 24 last week, seems to have resumed gains after a day of losses on Monday.Meanwhile, President Donald Trump escalated his long-standing conflict with Federal Reserve Chair Jerome Powell on Monday by threatening a lawsuit over alleged “gross incompetence,” a move that has reignited concerns regarding central bank independence just month ...

Group 1 - Azenta, Inc. has signed a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for a purchase price of US$63 million, with the transaction expected to close on or before March 31, 2026 [1][2] - The sale of B Medical Systems is aimed at simplifying Azenta's portfolio to focus on core capabilities that have the highest strategic impact, with proceeds intended to strengthen the company and drive long-term value creation for shareholders [2] - B Medical Systems is a global manufacturer and distributor of medical refrigeration devices based in Luxembourg [2] Group 2 - William Blair acted as the exclusive financial advisor, while Taylor Wessing served as legal counsel for Azenta in this transaction [3] - Azenta, Inc. is a leading provider of life sciences solutions, offering a full suite of cold-chain sample management solutions and multiomics services for pharmaceutical, biotech, academic, and healthcare institutions globally [4] - The company is headquartered in Burlington, MA, and operates in North America, Europe, and Asia [5]

Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and the leading supplier of proton therapy solutions for cancer treatment [5][6] - The company employs approximately 2,100 people globally and is based in Louvain-la-Neuve, Belgium [5] - IBA is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high standards of social and environmental performance [5][6] Contract Details - IBA has signed a contract with Seoul St. Mary's Hospital for the installation of a ProteusPLUS solution, which includes three gantry-rooms and a multi-year service contract [2][3] - The system will feature DynamicARC beam delivery capabilities once it receives regulatory clearance [2] - The hospital plans to begin patient treatments by the end of 2029, with the center covering a total area of 37,851 square meters [2] Market Impact - The contract signifies the growing demand for proton therapy solutions in South Korea, expanding the number of centers that utilize IBA's technology [3] - The typical end-user price for a three-room ProteusPLUS system with a multi-year maintenance contract ranges between €80 million and €100 million [3] Hospital Profile - Seoul St. Mary's Hospital is one of the largest hospitals in South Korea and a flagship institution of the Catholic Medical Center, providing comprehensive care across 45 departments [6] - The hospital has a global reputation for treating blood cancers and is also expanding its capabilities in treating solid tumors [3][6] - It has treated over 30,000 international patients from more than 100 countries and has trained over 900 international physicians through its fellowship programs [6]

Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [2] - The company operates globally with over 10,000 employees and a presence in more than 140 countries, divided into two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [3] - ResMed's products include industry-leading CPAP machines and software for durable medical equipment, focusing on out-of-hospital care [3][4] Market Performance - The ASX:RMD share price has decreased by 2.0% since the start of 2025 [1] - The S&P/ASX200 Healthcare Index has returned -4.53% per year over the last 5 years, contrasting with a 5.51% annual return from the broader ASX 200 [5] Revenue Stability - Healthcare spending is considered essential, leading to stable and consistent revenue streams, often referred to as 'sticky' revenue, which remains resilient during economic downturns [6] - Historical performance indicates that healthcare was the best-performing sector during the Global Financial Crisis (GFC) [6] Growth Potential - Global healthcare spending, particularly in the US, is projected to grow significantly, with estimates of 7% annual growth from 2022 to 2027, reaching US$819 billion [7] - Sub-sectors such as healthcare IT and SaaS are expected to see revenue growth exceeding 15% per year from 2024 to 2030, attracting investor interest [8] Ethical Investment Trends - A Morgan Stanley survey indicates that over half of investors plan to increase their allocation to sustainable investments in 2024, positioning healthcare sectors favorably for attracting new capital [9] Valuation Insights - ResMed shares currently have a price-to-sales ratio of 5.08x, below the 5-year average of 8.70x, suggesting that shares may be undervalued or that sales have increased [11]

TransMedics, Inc. is the manufacturer and supplier of its patented Organ Care System ( OCS ) that relies on warm-perfusion technologies to help transport viable organs long distances to recipients across theA longtime investor with a general interest in healthcare equities. I take a holistic investment approach that considers top-down and bottom-up valuation techniques. I find the more minute details of companies, including their capital structure and debt covenants, play an outsized role in equity valuatio ...